AI Healthcare is also 'Raising Lobsters': Health 160 Surges Over 80% in Four Days, What Exactly is the Market Betting On?

The capital market's sense of smell often moves one step faster than industrial transformation, but it is also more prone to misjudgment amid collective euphoria.

When a company once labeled as a "registration and referral" platform is suddenly redefined as "AI hospital infrastructure," the sharp fluctuations in its stock price are no longer merely an emotional release but a violent shift in its valuation framework.

Health 160 (02656.HK) saw its stock price surge more than threefold in less than seven months. Even under the immense pressure of an upcoming initial share lock-up expiration next week, it continued to rally sharply on March 12, surging another 13% to hit a new all-time high since listing.

Behind the sustained surge, what truly warrants review is not the rise itself, but what the market is actually betting on.

Two Extreme Swings in Sentiment

The stock price trajectory of Health 160 epitomizes the sentiment volatility along the tech theme in the Hong Kong stock market in 2026.

Just a month ago, on February 11, the stock plunged about 30% in a single day. The market's logic at that time was clear and cold: as a typical internet healthcare platform, Health 160, despite its narratives about AI healthcare, still showed slow revenue growth without profit improvement.

Data shows that the gross margin of its pharmaceutical sales business has long hovered around 1.4%. In the eyes of the capital market, this model of earning meager margins by selling drugs is an inefficient form of traffic monetization with no room for imagination.

Ultimately, the anticipation of the lock-up expiration, combined with doubts about the profitability of the sector, triggered a typical "sentiment stampede."

However, the market's narrative logic underwent a dramatic reversal within just a few days. Following the 2026 Government Work Report's first-time proposal to "foster new forms of the smart economy" and the explosive popularity of the open-source AI agent OpenClaw in tech circles, Health 160 swiftly adjusted its course, announcing plans to promote the deployment of AI agents, represented by OpenClaw, in hospital settings.

This move seemed to press the valuation switch, triggering a rocket-like surge in the stock price, which accumulated gains of over 80% in just four trading sessions. Since its listing in September 2025, its stock price has more than tripled.

Whether it's the short-term sharp volatility or the long-term technical strength, these are clearly not due to a qualitative change in the company's fundamentals overnight, but rather a forced rewrite of the valuation model. The market no longer views it as a low-frequency registration and referral tool but has begun pricing it using the logic of "AI infrastructure."

The essence of Health 160's stock surge is a violent correction of the old valuation system by the capital market, catalyzed by both policy tailwinds and tech hype.

Revaluation of Two Decades of "Hard Work": Pseudo "Healthcare OS" or a Real Moat?

From a market perspective, platform competition in the internet healthcare industry has long entered an era of giants.

In platform-based internet healthcare, there are AliHealth and JD Health; for doctor consultation platforms, there is Ping An Good Doctor; and for medical referral platforms, there is WeDoctor. Against these giants, Health 160 appears to have no advantage.

Yet, its latest disclosed operational data directly reveals some "hard work" that is difficult to replicate. Data shows that by the end of 2025, Health 160 had reached "160 AI Hospital" operational cooperation agreements with 82 public second-tier and above hospitals, adding 52 in the fourth quarter alone, a quarter-on-quarter increase of 420%.

This explosive growth in data actually unravels the truth of its core competitiveness. In the healthcare industry, technology can perhaps be bought, but the "pipeline" capability to enter and continuously operate within a hospital's core system is a scarce resource.

Healthcare institutions' extreme demands for data security, compliance, and stability create a very high industry barrier, making it difficult for most companies to quickly penetrate.

The ecosystem network that Health 160 spent two decades building, connecting over 44,000 medical institutions and 900,000 medical professionals, has precisely become the best soil for AI implementation.

When AI technology begins to enter the healthcare system, the large models themselves are easy to obtain, but few companies can truly deploy them. Health 160's deployment of OpenClaw and continuous improvement of related applications essentially involves embedding AI capabilities into hospital operational workflows.

In this process, Health 160's existing SaaS system and hospital relationship network become indispensable carriers.

As for Health 160, it can be said that it is rapidly transforming into a potential candidate for "China's Hospital OS." Its logic is to convert the originally low-frequency registration connection into high-frequency hospital operational services and data sharing. If this model proves viable, its business model will upgrade from a mere drug seller to an operator of industry infrastructure.

However, whether this means it truly possesses operating system-level control or merely serves as a supplementary plugin for HIS vendors still requires time to verify. After all, there is a vast execution gap between "connection" and "operation."

The Valuation Revolution in AI Healthcare: Why Capital Suddenly Began Repricing

The "AI Hospital" story is highly compelling, but Health 160 is at a delicate crossroads where the shadow of lock-up expiration intertwines with a potential profitability inflection point.

Next week, the company will face its initial share lock-up expiration. Facing selling pressure at historical highs is a critical moment to test the market's conviction. It's worth noting, however, that not long ago, Health 160 was officially included in the Stock Connect scheme, enhancing its liquidity.

Meanwhile, the capital market's optimistic expectations are built on aggressive assumptions: that high-margin (over 70%) digital healthcare solutions can scale rapidly, driving the company to turn profitable in 2026.

The HK$150 target price given by institutions like Huasheng Securities is based on mid-to-high revenue growth forecasts. However, this valuation shift still carries uncertainty.

Globally, giants like Teladoc have experienced severe market cap fluctuations, warning that AI healthcare stories lacking stable scenario entry points are highly prone to collapse. The current stock price rise is largely a preemptive overdraw by capital on policy tailwinds and concept speculation.

At its core, capital market trading in Health 160 revolves around three main logics: first, the healthcare data entry point, where accumulated doctor-patient resources are the core production factors in the AI era; second, the trillion-scale consumer healthcare referral market, where high-margin services like dentistry and medical aesthetics are seen as the real profit sources; and finally, the recently erupted medical AI logic.

Compared to the scenario deficiency faced by overseas peers like Zocdoc or Hims & Hers, Health 160's core advantage lies in its deep hospital network. If the "AI Hospital" model can be successfully replicated, the platform will upgrade from a mere traffic tool to a digital infrastructure for the industry.

Of course, the story's validity still depends on three key variables: whether the stickiness of the healthcare traffic entry point is strong enough to avoid the awkwardness of users "leaving after use"; whether the high-margin conversion in consumer healthcare can be realized as scheduled; and the depth of integration between healthcare data and AI.

The internet healthcare industry has entered the second half of "intensive cultivation," where traffic 红利 is fading, and technological operational capability becomes the key determinant of the ceiling.

For investors, Health 160 could either leverage its industry accumulation to grow into a "rent collector" in the medical AI era, or, under the dual blows of the lock-up expiration wave and performance falsification, revert to the valuation starting point of a "registration platform."

In this capital gamble, the market is paying a high premium for "possibility." Whether this premium can translate into real profits will determine whether this valuation revolution is a ticket to a new continent or the bursting of another bubble.

When the hype of "raising lobsters" subsides, the market will ultimately re-examine the authenticity of its profit model transformation.